Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think that's highly likely and if not I would become even more bullish. If the trial was an outright failure (and in the past even if it fails at all) SEC rules force them to divulge within 4 days. Management has certainly never played with original endpoints. My guess is Monday as well.
Yep. You play the game to take that shot and ignore the noise. We'll know soon
No doubt.
We either hit or we lose it all. Some hoped for results monday and didn't get them and may have traded out. Won't change results either way of course.
It's definitely weak hands. It's to be expected and the closer to Christmas the more may sit it out. The Anavex debacle probably made sure of that.
Its 50 friggin thousand shares dude. Who cares at this point?
Sure hope so. Alkon and the gang could use a Merry Christmas!
Some traders may try to time this thing (likely what we are seeing this afternoon) and may trip over dollars for dimes. As you say could come at any point now.
No way to know. I agree that the current most likely day, especially if data is good, would be next Monday though
The same people who have funded the 100 million in capital to run the trials over these years got in on another good deal. Nobody likes it but we're sitting on quite a bit of money in case the trial isn't clear cut.
Its just an exploratory endpoint really. A safety checkpoint and maybe a point of reference for the company to have an idea of any persistent benefit after dosing has stopped. It's not really relevant to primary endpoint in any way.
No we apparently shouldn't since the final, follow up check hasn't been completed but isn't part of primary endpoint. Its essentially 3 months after final dose. We should get that sometime late q1 or q2.
This is my busy season and I just know it's going to come out a day I can't follow. I mean even if it's bad its exciting to follow on game day. Fingers crossed!
If results are clearly good they won't have a problem spreading the word. If that flows over into January that's fine. It will be institutional interest that will stabilize the market cap. You should also see the bioequivalence approval, dosing study, and FragileX launch early next year. MS at some point. Most depends on the AD results being clearly presented regardless of exact date I imagine. If the share price takes its time in reaching a more fair valuation that's OK. Just don't give us a trainwreck of a rushed mess please.
I mean it is anecdotal but most anecdotal patients are just some type of heresay or youtube clip or something. These patients are well documented and studied in peer reviews. Doesn't mean placebo isn't in play at all. I imagine it is but that's one heck of a placebo effect.
This might give even more hesitation and I understand but this is additional anecdotal info but was published as part of a peer review. This was another of the compassionate use patients. Sir John Templeton was a 3d and his estate helped fund the Blanche Rockefeller Memory Care center where Alkon developed bryostatin.
"According to her husband, Jenni’s form of Alzheimer’s differed from what is commonly seen in older adults — she retained her long-term memory, but her motor skills and speech declined more rapidly than with traditional Alzheimer’s patients. By the time Jenni was enrolled in BRNI’s compassionate-use trial, she had been bedfast and mute for nearly a year. Spencer remembers the moment when, hours after her first dose of Bryostatin, she reached to him for a high five — her arm fully extended to meet his for the first time in months.
“The first night, I had a medicine alarm go off — I gave her medicine about seven times a day — and when it went off, she was upset and started vocalizing, trying to talk,” he said. “I was blown away by that, because she hadn’t done that for months. She was fussing, and so I said ‘Tell me what’s wrong, honey. I’ll do anything I can to help you.’ And she said, ‘hot.’ Speech had returned after 12 months of nothing, the day after the first dose.”
Jenni continued to improve as the trial progressed, according to Spencer. She regained more than 20 words over the next several weeks, he said, and could do many of the speech therapy tasks she had lost months before.
“This stuff works,” Spencer said. “She’d lost the ability to drink through a straw prior to the drug, and after she started taking it she regained her ability to drink through a straw and swallow. It was a really amazing thing to witness.”
Link in ibox.
Off on that IMO. It's not like this is simply anecdotal without documentation. Every single dose this guy got was documented. Pkce levels tested and recorded for 50 weeks and peer reviewed. Yes, its not all about regrowing synapses within hours. There are dozens of ways bryostatin works and restoring plasticity is one that wouldn't require some type of synaptic network rewiring. The rewiring is for the longer haul (or not at all of course). Read the link Cyosol reposted in the ibox on Jenni. Very similar situation as for response.
Carney's MMSE level was still more than double the start of trial essentially a year later. Too good to be true? Perhaps but the documentation is out there. First peer review showed multiple patients with large SIB increases. Well over the 4 average. Some patients see immediate impact for whatever reason. It wouldn't take regrowth to enhance the connectivity. Either way, certainly most think the whole process is too good to be true. What I'm saying is regrowing synapses isn't bryostatin's only modality by a long shot. GL
Both the link about Jenni fro West Virginia and about Frank Carney
Thanks
Several of the articles from the ibox are now behind paywalls unfortunately but I did find this one. https://www.kwch.com/content/news/Pizza-Hut-founder-sees-Alzheimers-symptoms-reverse-in-clinical-trial-566116201.html
100% agree.
Would be. of course there's well documented anecdotal results already from the compassion use patients.
You mean the same one that bashed the crap out of AVXL today?
For those who haven't seen it.
https://seekingalpha.com/article/4563543-synaptogenix-bryostatin-alzheimers-binary
Not necessarily. Just saying its been done here. Could be any day or any time now
100% correct. I remember the 1st go around (when they did the friday PR) results were out by 6:30 AM and 8:30 CC. I scheduled my week for a Monday PR lol. Can't follow at all on Tuesday or Thursday. Management if you are reading cut me a break!!!!
That's realistic. I'm thinking 20% blockbuster. 40% mixed. 40% failure.
Bought at 5. Obviously not a lot but just had to get a few
Lol. Wonderhow many times Perry will be wrong?
Certainly would be an overreaction but so is today's price. Hoping to not even have to worry about this
Yeah would probably go to a buck and then come back up towards 2 on failure. Whatever happens is OK with me. I agree with the cash and preclinical on several fronts that even if it fails would be acquired for something in current price range.
Certainly not but it certainly did happen today around the 5 buck mark couple hours after my post. You can always tell when it bounces to around 4.85 ish range and right back above the even dollar amount. Some think it might save them if results are bad but obviously would gap below. Now some folks are out of about 30-40k shares. Maybe it works out for them. Who knows. Stink bid missed by .04. There's always tomorrow I guess but hoping not to add.
Yes with the past accusations it makes a lot of sense. Smart move
Nice bump lately. Will be interesting to see the 12 month data in a few weeks
If anyone has stop orders in at 5, they will likely be hit. If anyone wants to add a few, put stinks bids in below that number. Otherwise let's close our eyes and pray for the best! We'll know soon.
Someone asked for a link to the article that Perry's quote came from this spring.
https://www.frontiersin.org/articles/10.3389/fnagi.2022.836634/full
I hope Perry is right in his hopes. No guarantees.
LOL. Based on the "data" over the last week, apparently not many believe that....because it doesn't show any such thing. Their trial didn't even ATTEMPT to do this. Primary endpoint is to slow decline. How do you claim a 40% decrease in decline if you stopped and reversed the disease? Would love to hear that one.
How many patients improved in the donezepil studies? Did they reverse the disease? https://alzres.biomedcentral.com/articles/10.1186/alzrt210#Tab2
Yep I follow about 20 companies that claim the same. I'll start with those that can stop the decline and actually reverse it first.
It wouldn't be a failure. That's why I say know what you own and don't listen to that type of spin because you'll hear it. You already are. Of course the higher the score the better. Of course it would be even more blockbuster if the score is over 4 at the halfway mark and plus 6 or higher at the end and that's what I dream of. Bryostatin works in a dozen+ ways and some may normalize growth factors to increase brain plasticity for a period of time and then resume a slower decline. Essentially a better version of what is already out there and you would be correct that it isn't a failure. What we found in the peer review and I just posted a quote from George Perry, is that the earlier bryostatin is given, before PKCe deficits, the potential of the drug to modify the disease increases. No reason to think it wouldn't work earlier and earlier in the AD course so if we do meet endpoints and keep the score at 4 or more points, it opens a lot of doors moving forward IMO.
I don't know if he does or not but all any of us have at this point is hope until FDA grants approvals. I know this is what he said about our peer review in April.
"George Perry, Chairman of Synaptogenix's Scientific Advisory Board and Semmes Distinguished University Chair in Neurobiology at the University of Texas, recognized for his work on oxidative stress in AD, stated, "Restoration of vascular and oxidative balance now joins synaptic function as Bryostatin's benefits, offering the hope that Bryostatin will cure the key deficits of Alzheimer's disease and aging. These findings support Protein Kinase C epsilon (PKC e) as a master regulator of aging and Bryostatin as a candidate for prevention and disease reversal."
Nope. If you mean used the word improvement to include some patients improved when the mean of the group declined then you are correct. All trials have patients that improve. ALL. I posted a link today that showed just how many donezepil patients improved at 48 weeks. Does donezepil improve AD? Nope. Did the Anavex endpoint objective say DECLINE? Yep. Did Perry say Anavex would need to confirm results from an additional trial? Absolutely he did.